
Sac-TMT is the first TROP2 ADC to improve OS compared to treatment of physician’s choice (TPC) in patients with advanced gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy in a global Phase 3 study
TroFuse-015 is the second positive Phase 3 readout from the global TroFuse clinical development program evaluating sac-TMT across multiple tumor types
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s choice (TPC, consisting of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel) in the treatment of patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy. TroFuse-015 represents the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 trial in this patient population, where there is significant unmet need. These data will be presented at an upcoming medical meeting and shared with regulatory authorities.
At final analysis, sac-TMT demonstrated a statistically significant and clinically meaningful improvement in OS compared to TPC for these patients who have received two or more prior lines of systemic therapy. Results were generally consistent across subgroups regardless of TROP2 expression status. Sac-TMT did not meet the secondary endpoint of progression-free survival (PFS) assessed by blinded independent central review (BICR). Additionally, sac-TMT showed a nominally improved benefit in objective response rate (ORR), a secondary endpoint, favoring sac-TMT compared with TPC, but this was not formally tested under the prespecified analysis plan. The safety profile was consistent with what has been observed in previously reported studies of sac-TMT; no new safety signals were observed.